Metraipolis › archive › dc_56416a5fa7c8
Adding Docetaxel to Tepotinib to Overcome Oligoprogression in MET Exon 14 Skipping-Mutated NSCLC When Local Therapy Is Unfeasible: A Case Report — Europe PMC PMID:40880848
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/40880848
- DOI
- 10.1155/crom/4483379
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-10T12:06:22.413Z
- SHA-256 of the archived text
fc020ca9f0c31ce5c06db73d82cd63e5f373cf86f6b9567f8f1194ee0b6971c5- Stable URL of this page
https://metraipolis.com/documento/dc_56416a5fa7c8
How to cite
Adding Docetaxel to Tepotinib to Overcome Oligoprogression in MET Exon 14 Skipping-Mutated NSCLC When Local Therapy Is Unfeasible: A Case Report — Europe PMC PMID:40880848 — Europe PMC (en), https://europepmc.org/article/MED/40880848 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_56416a5fa7c8 (Metraipolis archive dc_56416a5fa7c8, sha256 fc020ca9f0c31ce5c06db73d82cd63e5f373cf86f6b9567f8f1194ee0b6971c5)
BibTeX
@misc{dc56416a5fa7c8,
title = {Adding Docetaxel to Tepotinib to Overcome Oligoprogression in MET Exon 14 Skipping-Mutated NSCLC When Local Therapy Is Unfeasible: A Case Report — Europe PMC PMID:40880848},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/40880848},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_56416a5fa7c8; sha256 fc020ca9f0c31ce5c06db73d82cd63e5f373cf86f6b9567f8f1194ee0b6971c5},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40880848. Agents can read the archived copy with the MCP tool read_document.